risk of hbv reactivation in patients infected with hbv/hcv treated with daa

The exact number of hbv/hcv co-infected patients is unknown. in many cases of hbv/hcv co-infection, hcv inhibits replication of hbv. after treatment and eradication of the dominant virus, the other one may then become active. the overall dominant effect appears to be hepatitis c over hepatitis b. therefore, when planning treatment for eradication of hcv, the risk of hbv reactivation should be taken into account. in interferon-based therapies of patients with hbv/hcv co-infection, some cases of hbv reactivation without hepatitis were observed because ifn is effective against both viruses. in contrast, daa treatment of hepatitis c in hbv/hcv co-infection is not well established. currently, no clinical trials have been published regarding treatment of hbv/hcv co-infected patients with hcv daa therapy. there is several research on hcv daa therapy in hbv/hcv co-infection, which describes cases of hbv reactivation during and after dda therapy for hcv. result of the first available studies demonstrated that patients with hbv/hcv co-infection treated with daa against hcv should be monitored for hbv reactivation during and after daa treatment, even though hbv may be inactive at the time of treatment initiation.